Endocan: A novel inflammatory indicator in cardiovascular disease?

被引：184

作者：

Balta, Sevket ^{[1
]}

Mikhailidis, Dimitri P. ^{[2
]}

Demirkol, Sait ^{[1
]}

Ozturk, Cengiz ^{[1
]}

Celik, Turgay ^{[1
]}

Iyisoy, Atila ^{[1
]}

机构：

[1] Gulhane Mil Med Acad, Dept Cardiol, Ankara, Turkey

[2] UCL, Sch Med, Dept Clin Biochem, London WC1E 6BT, England

来源：

ATHEROSCLEROSIS | 2015年 / 243卷 / 01期

关键词：

Endocan; Inflammation; Atherosclerosis; Endothelial dysfunction; Cell adhesion; CELL-SPECIFIC MOLECULE-1; CHRONIC KIDNEY-DISEASE; HYPERTENSIVE PATIENTS; ADHESION MOLECULES; BEHCET-DISEASE; ARTERIAL STIFFNESS; PSORIASIS-VULGARIS; LYMPHOCYTE RATIO; MARKER; ENDOTHELIUM;

D O I：

10.1016/j.atherosclerosis.2015.09.030

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Endothelial dysfunction is considered as an early change in atherogenesis. Raised levels of systemic inflammatory markers are associated with cardiovascular disease (CVD). Endocan (previously known as endothelial cell specific molecule-1, ESM-1), is a potential immunoinflammatory marker that may be linked to CVD. Endocan is released by vascular endothelial cells in several organs. Endocan may play an important role in regulating cell adhesion and raised plasma levels may reflect endothelial dysfunction. Endocan levels are elevated in conditions such as chronic kidney disease, renal transplant rejection, tumor progression and hypertension. Endocan is a potential inflammatory and CVD marker. Further studies are needed to assess the relevance of endocan in clinical practice. (C) 2015 Elsevier Ireland Ltd. All rights reserved.

引用

页码：339 / 343

页数：5

共 46 条

[1] Vascular endocan is preferentially expressed in tumor endothelium [J].